Gleam Publishing

✨Shining Knowledge Forward—illuminating ideas that shape tomorrow’s world. Provide trusted, peer-reviewed platforms for researchers to share high-quality works.

[Gleam Publishing @Gleampublishing]

📢 New Article | Journal of Clinical Question
A methodological review: heterogeneity in meta-analysis
🔹 Understanding heterogeneity
🔹 Quantifying heterogeneity
🔹 Exploring heterogeneity
🔹 Clinical interpretation
📚 Read it: https://t.co/FMYUsMGonE
#MetaAnalysis

[Gleam Publishing @Gleampublishing]

📘 NEW REVIEW | Journal of Clinical Question

🔬 Direct RAS targeting in PDAC has rapidly evolved from proof of concept to Phase III clinical validation. This timely review provides an overview of the rapidly changing therapeutic landscape.

🌐 Read it: https://t.co/oAGJeCWrfx

[Gleam Publishing @Gleampublishing]

📘 NEW REVIEW | Journal of Clinical Question

🔬 Direct RAS targeting in PDAC has rapidly evolved from proof of concept to Phase III clinical validation. This timely review provides an overview of the rapidly changing therapeutic landscape.

🌐 Read it: https://t.co/oAGJeCWrfx

[Gleam Publishing @Gleampublishing]

📘 NEW REVIEW | Journal of Clinical Question

🔬 Direct RAS targeting in PDAC has rapidly evolved from proof of concept to Phase III clinical validation. This timely review provides an overview of the rapidly changing therapeutic landscape.

🌐 Read it: https://t.co/oAGJeCWrfx

[Gleam Publishing @Gleampublishing]

📘 NEW REVIEW | Journal of Clinical Question

🔬 Direct RAS targeting in PDAC has rapidly evolved from proof of concept to Phase III clinical validation. This timely review provides an overview of the rapidly changing therapeutic landscape.

🌐 Read it: https://t.co/oAGJeCWrfx

[Gleam Publishing @Gleampublishing]

"Bispecific Antibodies Targeting PD-1/PD-L1 and VEGF in Non-Small Cell Lung Cancer" — Read it on @ResearchGate: https://t.co/JljOA49xpp

[Gleam Publishing @Gleampublishing]

🌟 A new review summarizes the current clinical evidence for PD-(L)1/VEGF bispecific antibodies in NSCLC and discusses their potential role in future treatment strategies.
👉 Read it: https://t.co/nszXQB864J
#NSCLC #PD1 #PDL1 #VEGF

[Gleam Publishing @Gleampublishing]

🌟 A new review summarizes the current clinical evidence for PD-(L)1/VEGF bispecific antibodies in NSCLC and discusses their potential role in future treatment strategies.
👉 Read it: https://t.co/nszXQB864J
#NSCLC #PD1 #PDL1 #VEGF

[Gleam Publishing @Gleampublishing]

🌟A new review summarizes the current clinical evidence for PD-(L)1/VEGF bispecific antibodies in NSCLC and discusses their potential role in future treatment strategies.
👉 Read it: https://t.co/nszXQB864J
#NSCLC #PD1 #PDL1 #VEGF

[Gleam Publishing @Gleampublishing]

🌟New Review in the Journal of Clinical Question
🔎 A new review summarizes the current clinical evidence for PD-(L)1/VEGF bispecific antibodies in NSCLC and discusses their potential role in future treatment strategies.
👉 Read it: https://t.co/nszXQB864J
#NSCLC #PD1 #PDL1 #VEGF

[Gleam Publishing @Gleampublishing]

🌟 New Review in the Journal of Clinical Question
❓ What factors affect the efficacy of PD-(L)1 inhibitors in patients with non-small cell lung cancer?
🔎 A new review summarizes the complex interactions
👉 Read it: https://t.co/NlU7XT2VPk

#NSCLC #Immunotherapy #PD1 #PDL1

[Gleam Publishing @Gleampublishing]

"Thrombopoietin Receptor Agonists for Chemotherapy-Induced Thrombocytopenia: A Systematic Review and Network Meta-Analysis" — Read it on @ResearchGate: https://t.co/xaSNIqivt4

[Gleam Publishing @Gleampublishing]

🌟New Meta-Analysis
Chemotherapy-induced thrombocytopenia (CIT) can lead to chemotherapy delays, dose reductions, and the need for platelet transfusions. Which TPO receptor agonist provides the best efficacy for CIT❓
👉Read it: https://t.co/ZFx5mEKC40

[Gleam Publishing @Gleampublishing]

🌟New Meta-Analysis
Chemotherapy-induced thrombocytopenia (CIT) can lead to chemotherapy delays, dose reductions, and the need for platelet transfusions. Which TPO receptor agonist provides the best efficacy for CIT❓
👉Read it: https://t.co/ZFx5mEKC40

[Gleam Publishing @Gleampublishing]

🌟New Meta-Analysis Chemotherapy-induced thrombocytopenia (CIT) can lead to chemotherapy delays, dose reductions, and the need for platelet transfusions. Which TPO receptor agonist provides the best efficacy for CIT❓ 👉Read it: https://t.co/ZFx5mEKC40

[Gleam Publishing @Gleampublishing]

🌟New Meta-Analysis
Chemotherapy-induced thrombocytopenia (CIT) can lead to chemotherapy delays, dose reductions, and the need for platelet transfusions. Which TPO receptor agonist provides the best efficacy for CIT❓
👉Read it: https://t.co/ZFx5mEKC40

[Gleam Publishing @Gleampublishing]

"Cell Therapy for Solid Tumours: From an Exceptional iNKT-Cell Response to a Testable Therapeutic Platform" — Read it on @ResearchGate: https://t.co/xzgj8jjsy6

[Gleam Publishing @Gleampublishing]

🧬 A new Commentary in Journal of Clinical Question explores the potential of iNKT-cell–based therapy for solid tumours, inspired by an exceptional case report showing a durable response to allogeneic iNKT cells combined with dendritic cells.
👉 Read it: https://t.co/Okt7HWioyA

[Gleam Publishing @Gleampublishing]

"KRAS-Targeted Therapy in Non–Small Cell Lung Cancer: Current Standards, Resistance Mechanisms, and Emerging Therapeutic Strategies" — Read it on @ResearchGate: https://t.co/xUlnBBWrSS

[Gleam Publishing @Gleampublishing]

✨New Review in the Journal of Clinical Question summarizes the current standards of KRAS-targeted therapy in NSCLC, with a focus on resistance mechanisms and emerging therapeutic strategies.
👉Read it: https://t.co/rNChccDxG5
#LungCancer #NSCLC #KRAS